MCM6: A Potential Drug Target for Diseases (G4175)
MCM6: A Potential Drug Target for Diseases
MCM6 (Muramylated-C and flattenediolase 6) is a protein that is expressed in various tissues of the body, including the brain, heart, kidneys, and liver. It is a key enzyme in the metabolization of cell membrane phospholipids, which are an essential component of cell structure and function. MCM6 is also involved in the transport of lipids across cell membranes, as well as in the production of various signaling molecules.
Recent studies have identified MCM6 as a potential drug target for a variety of diseases, including cardiovascular disease, neurodegenerative diseases, and liver diseases. This is because MCM6 is involved in the regulation of cellular signaling pathways that are involved in the development and progression of these diseases.
One of the reasons why MCM6 is thought to be a promising drug target is because it is involved in the production of various signaling molecules that are involved in cell signaling pathways that are involved in the development and progression of many diseases. For example, MCM6 is involved in the production of various signaling molecules that are involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.
MCM6 is also involved in the production of various signaling molecules that are involved in the regulation of cellular signaling pathways that are involved in the development and progression of cardiovascular disease. the regulation of angiogenesis, which is the process by which new blood vessels are formed in the body.
Another reason why MCM6 is thought to be a promising drug target is because it is involved in the regulation of cellular signaling pathways that are involved in the development and progression of liver diseases. For example, MCM6 is involved in the production of various signaling molecules that are involved in the regulation of fibrosis, which is the process by which cells become abnormally organized and form tissue.
In addition to its involvement in cellular signaling pathways, MCM6 is also thought to be involved in the regulation of various cellular processes that are involved in the development and progression of diseases. For example, MCM6 is involved in the regulation of cellular processes that are involved in the production and degradation of various signaling molecules, as well as in the regulation of cellular processes that are involved in the production and degradation of various signaling molecules.
Overall, MCM6 is a protein that is involved in a variety of cellular processes that are involved in the development and progression of diseases. As a result, it is a potential drug target for a variety of diseases, including cardiovascular disease, neurodegenerative diseases, and liver diseases. Further research is needed to fully understand the role of MCM6 in these diseases and to develop effective treatments.
Protein Name: Minichromosome Maintenance Complex Component 6
Functions: Acts as component of the MCM2-7 complex (MCM complex) which is the replicative helicase essential for 'once per cell cycle' DNA replication initiation and elongation in eukaryotic cells. Core component of CDC45-MCM-GINS (CMG) helicase, the molecular machine that unwinds template DNA during replication, and around which the replisome is built (PubMed:32453425, PubMed:34694004, PubMed:34700328, PubMed:35585232, PubMed:16899510, PubMed:9305914). The active ATPase sites in the MCM2-7 ring are formed through the interaction surfaces of two neighboring subunits such that a critical structure of a conserved arginine finger motif is provided in trans relative to the ATP-binding site of the Walker A box of the adjacent subunit. The six ATPase active sites, however, are likely to contribute differentially to the complex helicase activity (PubMed:32453425)
The "MCM6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MCM6 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MCM7 | MCM8 | MCM8-MCM9 complex | MCM9 | MCMBP | MCMDC2 | MCOLN1 | MCOLN2 | MCOLN3 | MCPH1 | MCPH1-AS1 | MCPH1-DT | MCRIP1 | MCRIP2 | MCRS1 | MCTP1 | MCTP2 | MCTS1 | MCTS2 | MCU | MCUB | MCUR1 | MDC1 | MDFI | MDFIC | MDGA1 | MDGA2 | MDH1 | MDH1B | MDH2 | MDK | MDM1 | MDM2 | MDM4 | MDN1 | MDS2 | ME1 | ME2 | ME3 | MEA1 | MEAF6 | MEAF6P1 | MEAK7 | Mechanoelectrical transducer (MET) channel | Mechanosensitive Ion Channel | MECOM | MECOM-AS1 | MeCP1 histone deacetylase (HDAC) complex | MECP2 | MECR | MED1 | MED10 | MED11 | MED12 | MED12L | MED13 | MED13L | MED14 | MED14P1 | MED15 | MED15P8 | MED16 | MED17 | MED18 | MED19 | MED20 | MED21 | MED22 | MED23 | MED24 | MED25 | MED26 | MED27 | MED28 | MED29 | MED30 | MED31 | MED4 | MED4-AS1 | MED6 | MED7 | MED8 | MED9 | MEDAG | Mediator Complex | Mediator of RNA Polymerase II Transcription | MEF2A | MEF2B | MEF2C | MEF2C-AS1 | MEF2C-AS2 | MEF2D | MEFV | MEG3 | MEG8 | MEG9 | MEGF10 | MEGF11 | MEGF6 | MEGF8
